Table 3.

Stage of PrEP use continuum reached by PrEP Well participants across each phase

Participant-level Efficacy Outcomes	All Phases 8/1/22 – 1/31/24	Implementation Phase I 8/1/22 – 1/31/23	Implementation Phase II 2/1/23 – 7/31/23	Sustainment Phase III 8/1/23 – 1/31/24	X2 statistic, p-value
	n (%)	n (%)	n (%)	n (%)
Received peer outreach, HIV testing, and peer navigation (baseline visit).	N = 113	n = 27	n = 36	n = 50
Attended PrEP visit with provider, labs provided, and PrEP prescription written	60 (53.1)	13 (48.2)	18 (50.0)	29 (58.0)	X2(2) = 0.88, p =.64
Returned for 30-day visit and urinalysis showed PrEP uptake	50 (83.3)	10 (76.9)	15 (83.3)	25 (86.2)	X2(2) = 0.55, p =.76
Returned for 90-day visit and urinalysis showed sustained PrEP use	44 (73.3)	6 (46.2)*	18 (100.0)+*	20 (70.0)	X2(2) = 11.73, p <.01
Returned for 90-day visit and dried blood spots showed PrEP adherence	40 (66.7)	6 (46.2)**	15 (83.3)**	19 (65.5)	X2(2) = 4.74, p <.05

Note: Rates of clients who demonstrated PrEP uptake, sustained use, and adherence are compared against the number of clients who attended PrEP visit and received a PrEP prescription (denominator)

⁺3 clients missed their 30-day return visits but returned for 90-day visit and demonstrated PrEP uptake

^*Phase I and Phase II post hoc tests were significantly different at 90-day visit for sustained PrEP use via urinalysis X²(1) = 9.75, p <.001

^**Phase I and Phase II post hoc tests were significantly different at 90-day visit for PrEP adherence use via dried blood spot assay X²(1) = 4.70, p <.05